Legend:
CC = Vancouver Convention Centre
F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
368
Tue, 7/31/2018,
11:35 AM -
12:20 PM
CC-West Hall B
SPEED: Statistics for Biopharmaceutical Studies — Contributed Poster Presentations
Biopharmaceutical Section , Section on Bayesian Statistical Science
Chair(s): Paul McNicholas, McMaster University
Oral Presentations
for this session.
21:
Probabilistic Modeling of Sleep and Awake States in Alzheimer's Disease
Cici Bauer, Pfizer, Inc ; Charmaine Demanuele, Pfizer, Inc. ; Dmitri Volfson, Pfizer
22:
Integrative Statistical Analysis Pipeline for RNA-Seq and NanoString with Application to Gene Expression Data of Cancer Patients
Jeea Choi, Novartis Pharmaceuticals ; Catarina D. Campbell, Novartis Institutes for BioMedical Research; Xiaoshan Wang, Novartis Pharmaceuticals; He Wei, Novartis Pharmaceuticals; Robinson Douglas, Novartis Pharmaceuticals; Stephane Wong, Novartis Pharmaceuticals; Bin Fu, Novartis Pharmaceuticals; Rebecca Leary, Novartis Institutes for BioMedical Research; Kavitha Venkatesan, Novartis Institutes for BioMedical Research; Ying A Wang, Novartis Pharmaceuticals
23:
Bridging Information Between Dose-Response Curves Across Populations in Early Phase Clinical Trials
Moreno Ursino, Inserm DR PA 6
24:
A Simultaneous PK/PD Model for Muscle Relaxant Using Muscle Twitch Counts
Elizabeth Sigworth ; Matthew S Shotwell, Vanderbilt University
25:
STEPDOWN TESTING PROCEDURES for DOSE FINDING STUDY with ADAPTIVE DESIGN
Gang Jia, Merck & Co.
26:
Conditional Power Calculation for the Interim Monitoring of Cluster-Randomized Trials with Interval-Censored Endpoints
Kaitlyn Cook, Harvard University ; Rui Wang, Harvard Pilgrim HealthCare Institute
27:
Explore Modified Organ Dysfunction Score System to Improve the Prediction of Survival
Grace Zhang, GSK
28:
Discovering Biomarkers Jointly Modeled with Multiple Efficacy Variables in Early Phase Clinical Trials
Danni Yu, Eli Lilly and Company
29:
Extended Rank Tests for Analyzing Recurrent Event Data
Qiang Zhao ; Mark Chang, Veristat; Michael LaValley, Boston University; Joseph M. Massaro, Boston University; Bin Zhang, Seqirus; Kathryn Lunetta, Boston University
30:
A Study in the Use of Unsupervised Random Forest in the Analysis of Data Sets Composed of Categorical Variables/Features
Nelson Lee Afanador, Merck ; Richard Baumgartner, Merck; Dai Feng, Merck
31:
A Statistical Evaluation of Cardiovascular Measurements Collected via Mobile Health Technology and Traditional Tools
Qinlei Huang, Merck ; Lori Mixson, Merck
32:
Method for Evaluating Longitudinal Follow-Up Frequency: Application to Dementia Research
Leah Suttner, University of Pennsylvania ; Sharon X Xie, University of Pennsylvania
33:
Performance Comparison of Post-Hoc Subgroup Search Algorithms for Clinical Trials
Victor Talisa, University of Pittsburgh ; (Joyce) Chung-Chou H. Chang, University of Pittsburgh
34:
Relationship Between ORR, PFS and OS in Patients Treated with Anti-PD1/PDL1 Therapies
Jiabu Ye, AstraZeneca ; Pralay Mukhopadhyay, Astrazeneca; Xiang Ji, AstraZeneca
35:
Real-Time Study Milestone Projection in Clinical Trials with Time-To-Event Endpoints
Yanping Liu, Merck & Co. ; Gang Jia, Merck & Co.
36:
Sensitivity to Infusion and Blood Draw Time Recording Errors in Pharmacokinetic Modeling
Hannah Weeks, Vanderbilt University ; Matthew S Shotwell, Vanderbilt University
37:
A Testing Paradigm for Earl Biomedical Research with Many Correlated Tests
Robert Montgomery ; Jonathan D Mahnken, University of Kansas Medical Center
